Risk factors and clinical outcomes of cytomegalovirus diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation
Purpose This study aims to evaluate the risk factors and prognosis for CMV diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation (HSCT). Methods We performed a case-control study (1:2) between 2012 and 2022. Adults with pathologic-confirmed CMV diseases (n=60) among hematologic malignancy patients were matched and compared to whom without CMV disease. Results Lymphoma was the most common underlying malignancy, and gastrointestinal tract involvement was the most common CMV disease. In the case group, high-dose steroid administration and transfusion within one month before diagnosis were higher (p<0.001). Steroid administration (aOR=5.78; 95% confidence interval: 1.25–26.68, p=0.024), red blood cell transfusion within one month (aOR=14.63; 2.75–77.76, p=0.002), low BMI (aOR=13.46, 2.07–87.45, p=0.006), and hypoalbuminemia (aOR=26.48, 5.93–118.17, p<0.001) were independent risk factors associated with CMV disease. The 30-day mortality was higher in the case group and CMV disease was significantly associated with all-cause mortality (aOR=14.41, 3.23–64.31, p<0.001). Conclusion In hematologic malignancy patients without HSCT, risk factors for CMV organ disease included high-dose steroid administration and RBC transfusion within one month, low BMI, and hypoalbuminemia. Overall mortality was significantly higher with CMV disease, and CMV disease occurrence was a significant risk factor for mortality..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Supportive care in cancer - 32(2023), 1 vom: 22. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Jinyoung [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00520-023-08258-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054162351 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054162351 | ||
| 003 | DE-627 | ||
| 005 | 20240116064632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00520-023-08258-5 |2 doi | |
| 035 | |a (DE-627)SPR054162351 | ||
| 035 | |a (SPR)s00520-023-08258-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Jinyoung |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk factors and clinical outcomes of cytomegalovirus diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose This study aims to evaluate the risk factors and prognosis for CMV diseases in hematologic malignancy patients without hematopoietic stem-cell transplantation (HSCT). Methods We performed a case-control study (1:2) between 2012 and 2022. Adults with pathologic-confirmed CMV diseases (n=60) among hematologic malignancy patients were matched and compared to whom without CMV disease. Results Lymphoma was the most common underlying malignancy, and gastrointestinal tract involvement was the most common CMV disease. In the case group, high-dose steroid administration and transfusion within one month before diagnosis were higher (p<0.001). Steroid administration (aOR=5.78; 95% confidence interval: 1.25–26.68, p=0.024), red blood cell transfusion within one month (aOR=14.63; 2.75–77.76, p=0.002), low BMI (aOR=13.46, 2.07–87.45, p=0.006), and hypoalbuminemia (aOR=26.48, 5.93–118.17, p<0.001) were independent risk factors associated with CMV disease. The 30-day mortality was higher in the case group and CMV disease was significantly associated with all-cause mortality (aOR=14.41, 3.23–64.31, p<0.001). Conclusion In hematologic malignancy patients without HSCT, risk factors for CMV organ disease included high-dose steroid administration and RBC transfusion within one month, low BMI, and hypoalbuminemia. Overall mortality was significantly higher with CMV disease, and CMV disease occurrence was a significant risk factor for mortality. | ||
| 650 | 4 | |a Cytomegalovirus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CMV organ disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hematologic malignancy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kang, Cheol-In |4 aut | |
| 700 | 1 | |a Lee, Young Ho |4 aut | |
| 700 | 1 | |a Ko, Jae-Hoon |4 aut | |
| 700 | 1 | |a Huh, Kyungmin |4 aut | |
| 700 | 1 | |a Cho, Sun Young |4 aut | |
| 700 | 1 | |a Chung, Doo Ryeon |4 aut | |
| 700 | 1 | |a Peck, Kyong Ran |4 aut | |
| 700 | 1 | |a Jung, Chul Won |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Supportive care in cancer |d Berlin : Springer, 1993 |g 32(2023), 1 vom: 22. Dez. |w (DE-627)SPR006567584 |w (DE-600)1463166-0 |x 1433-7339 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:1 |g day:22 |g month:12 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00520-023-08258-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 1 |b 22 |c 12 | ||